Central sensitisation and cutaneous allodynia in migraine: Implications for treatment

CNS Drugs

Volumn 18, Issue 6, 2004, Pages 337-342

  Landy, Stephen ^a,d   Rice, Kathryn ^b   Lobo, Bob ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; ALMOTRIPTAN; ANTIMIGRAINE AGENT; BRADYKININ; ELETRIPTAN; FROVATRIPTAN; GLUTAMIC ACID DERIVATIVE; HISTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NARATRIPTAN; PROSTAGLANDIN E2; RIZATRIPTAN; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; TRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ALLODYNIA; ANALGESIA; ANESTHESIA; BLOOD VESSEL; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COUGHING; DRUG EFFECT; HEADACHE; HUMAN; MIGRAINE; NERVE CELL; NEUROGENIC INFLAMMATION; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; SKIN SENSITIZATION; SPINAL CORD; STEM CELL; THALAMUS; TRIGEMINAL NERVE; VASODILATATION;

CENTRAL NERVOUS SYSTEM; HUMANS; HYPERALGESIA; HYPERESTHESIA; MIGRAINE DISORDERS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; SEROTONIN AGONISTS; SKIN DISEASES;

EID: 2442595065     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418060-00001     Document Type: Review

References (23)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-57
2. Mathew NT. Pathophysiology, epidemiology, and impact of migraine. Clin Cornerstone 2001; 4: 1-17
3. Graham JR, Wolff HG. Mechanisms of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938; 39: 737-63
4. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med Clin North Am 2001; 85 (4): 911-41
5. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001; 89: 107-10
6. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614-24
7. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002; 346: 257-70
8. Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 2003; 61 Suppl. 4: S2-8
9. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658-60
10. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7: 359-90
11. Diesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981; 9: 344-52
12. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136-47
13. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384: 560-4
14. Burstein R, Yamamura H, Malick A, et al. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998; 79: 964-82
15. Burstein R, Woolf CJ. The headaches. 2nd ed. Central sensitization and headache. Philadelphia (PA): Lippincott Williams & Wilkins, 2000
16. Silberstein SD. Neurotoxins in the neurobiology of pain. Headache 2003; 43: S2-8
17. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703-9
18. Levy D, Jakuabowski M, Burnstein R. Differential effects of sumatriptan on peripheral and central trigeminovascular neurons reveal site of action critical for terminating migraine [abstract]. Cephalalgia 2003; 23: 577
19. Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833-42
20. Pascual J, del Arco C, Romon T, et al. Autoradiographic distribution of [H3]sumatriptan-binding sites in post-mortem human brain. Cephalalgia 1996; 16: 317-22
21. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004; 55 (1): 25-36
22. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55 (1): 19-26
23. Landy SH, McGinnis JE, McDonald SA. Clinical indicators of cutaneous allodynia in patients who treated early with 100mg sumatriptan tablets [abstract S32.006]. 55th Annual Scientific Meeting of the American Academy of Neurology; 2003 Mar 29-Apr 5; Honolulu, Hawaii